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Objectives: While depression and heart disease often co-occur in Western countries, less is known about the association of anxiety and
alcohol use disorders with heart disease and about the cross-cultural consistency of this association. Consistency across emotional disorders
and cultures would suggest that relatively universal mechanisms underlie the association.
Methods: Surveys with 18 random population samples of household-residing adults in 17 countries in Europe, the Americas, the Middle
East, Africa, Asia and the South Pacific were carried out. Medically recognized heart disease was ascertained by self-report. Mental disorders
were assessed with the World Mental Health Composite International Diagnostic Interview, a fully structured diagnostic interview.⁎ Corresponding author. Tel.: +31 50 361 2078; fax: +31 50 3619722.
E-mail address: j.ormel@med.umcg.nl (J. Ormel).
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326 J. Ormel et al. / General Hospital Psychiatry 29 (2007) 325–334Results: Specific mood and anxiety disorders occurred among persons with heart disease at rates higher than those among persons without
heart disease. Adjusted for sex and age, the pooled odds ratios (95% confidence interval) were 2.1 (1.9–2.5) for mood disorders, 2.2 (1.9–
2.5) for anxiety disorders and 1.4 (1.0–1.9) for alcohol abuse/dependence among persons with versus those without heart disease. These
patterns were similar across countries.
Conclusions: An excess of anxiety disorders and that of mood disorders are found among persons with heart disease. These associations hold
true across countries despite substantial between-country differences in culture and mental disorder prevalence rates. These results suggest
that similar mechanisms underlie the association and that a broad spectrum of mood–anxiety disorders should be considered in research on
the comorbidity of mental disorders and heart disease.
© 2007 Elsevier Inc. All rights reserved.Keywords: Heart disease; Depression; Anxiety; Substance abuse; Cross-national1. Introduction
Depression and ischemic heart disease are leading sources
of disease burden worldwide [1–3]. Prior research found that
persons with heart disease are more likely to experience
depressive illness and that comorbid depression is associated
with a twofold or greater increased risk for all-cause
mortality, cardiovascular mortality and new cardiovascular
events [4–7], but a body of convincing evidence showing
that effective treatment of depression improves the prognosis
of heart disease is lacking [8–10]. Multiple comorbidity
mechanisms have been proposed to explain the association,
including health-related behaviors, impairments in auto-
nomic function, elevated levels of proinflammatory cyto-
kines and increased platelet function (e.g., [6,11–14]).
To date, research on heart disease–mental disorder
comorbidity had focused on depression and had largely
been conducted in Western countries [15–18]. Less is known
about the association of heart disease with anxiety or alcohol
use disorders or about mental–physical comorbidity in
developing countries and non-Western cultures. Using data
from World Mental Health (WMH) surveys in 17 countries
in Europe, the Americas, Asia, the Middle East and Africa,
we provide new information regarding the occurrence of
common mental disorders among persons with heart disease
and the consistency of the association across diverse Western
and non-Western countries. It is important to know such data.
If the association between heart disease and mental disorder
is not limited to depression and Western countries but
consistently observed around the world and for mental
disorders other than depression, then the position that
relatively universal mechanisms underlie the association
would be supported.
Studying mental–physical comorbidity for heart disease
via morbidity surveys in a wide range of developing countries
necessitated reliance on self-report data. Mental disorders
were assessed using a standardized diagnostic instrument.
Regarding heart disease, respondents were asked if a medical
doctor or any other health professional had ever told them that
they had a heart disease. Although the WMH surveys were
unable to confirm self-reports of medically diagnosed heart
disease by independent means, validity studies had shown
that similar measures have acceptable validity when com-
pared with medical records, with κ values generallyexceeding 0.60, sensitivities of 0.70 or greater and specifi-
cities of approximately 0.95 [19–22]. While it is certainly
possible that recall bias due to mental illness affects research
on perceived health and symptoms, it is far less so the case in
research on medically diagnosed disorders (e.g., [23,24]).
While the limitations of self-report of medically recognized
heart disease need to be borne in mind, this article presents
new information on the association of heart disease with
mood, anxiety and alcohol use disorders in diverse countries
worldwide. The objectives of our analysis were to (1) estimate
the prevalence of specific mood, anxiety and alcohol use
disorders among persons with and those without heart disease
and (2) assess whether these associations are consistent across
culturally and socioeconomically diverse countries.2. Methods
2.1. Samples
Eighteen surveys were carried out in 17 countries in the
Americas (Colombia, Mexico and United States), Europe
(Belgium, France, Germany, Italy, The Netherlands, Spain
and Ukraine), the Middle East/Africa (Israel, Lebanon,
Nigeria and South Africa), Asia (Japan and the People's
Republic of China, with separate surveys in Beijing and
Shanghai) and the South Pacific (New Zealand). All surveys
were based on multistage and clustered area probability
household samples. All interviews were carried out face to
face by trained lay interviewers. The six Western European
surveys were carried out jointly.
Internal subsampling was used to reduce respondent
burden by dividing the interview into two parts (except for
Israel). Part 1 included the core diagnostic assessment of
mental disorders, whereas Part 2 included collection of
additional information relevant to a wide range of survey
aims, including assessment of chronic physical conditions.
All respondents completed Part 1. All Part 1 respondents who
met the criteria for any mental disorder and a probability
sample of other respondents were administered Part 2. The
results from Part 2 respondents were weighted by the inverse
of their probability of selection for Part 2 of the interview to
adjust for differential sampling. Analyses reported in this
article were based on the weighted Part 2 sample. Additional
weights were used to adjust for differential probabilities of
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population sociodemographic distributions. The samples
showed substantial cross-national differences in age structure
(younger in less developed countries) and educational status
(lower in less developed countries) but not in sex distribution.
2.2. Training and field procedures
The central WMH staff trained bilingual supervisors in
each country. Consistent interviewer training documents and
procedures were used across surveys. The World Health
Organization (WHO) translation protocol was used to
translate instruments and training materials. Standardized
descriptions of the goals and procedures of the study, data
usage and protection and the rights of respondents were
provided in written and verbal forms to all potentially
eligible respondents before obtaining their verbal informed
consent for participation in the survey. Quality control
protocols, described in more detail elsewhere [25], were
standardized across countries to check on interviewer
accuracy and specify data cleaning as well as coding
procedures. The institutional review board of the organiza-
tion that coordinated the survey in each country approved
and monitored compliance with procedures for obtaining
informed consent and protecting human subjects.
2.3. Mental disorder status
All surveys used the WMH Survey Version 3.0 of the
WHO Composite International Diagnostic Interview [26], aTable 1
Characteristics of and heart disease prevalence rates for the samples
Country Sample (n) Mean age
(years) a
Aged 60 years
or older (%)
Americas
Colombia 2381 36.6 5.3
Mexico 2362 35.2 5.2
United States 5692 45.0 21.2
Asia and South Pacific
Japan 887 51.4 34.9
PRC Beijing 914 39.8 15.6
PRC Shanghai 714 42.9 18.7
New Zealand 7312 44.6 20.7
Europe
Belgium 1043 46.9 27.3
France 1436 46.3 26.5
Germany 1323 48.2 30.6
Italy 1779 47.7 29.2
The Netherlands 1094 45.0 22.7
Spain 2121 45.5 25.5
Ukraine 1720 46.1 27.3
Middle East and Africa
Lebanon 602 40.3 15.3
Nigeria 2143 35.8 9.7
Israel 4859 44.4 20.3
South Africa 4315 37.1 8.8
NA, not available.
a Minimum age is 18 years, except for Colombia, Mexico (age range, 18–65
b Lifetime prevalence reported.fully structured diagnostic interview, to assess disorders and
treatments. Disorders considered in this article include
anxiety [generalized anxiety disorder (GAD), panic disorder
and/or agoraphobia, posttraumatic stress disorder (PTSD)
and social phobia], mood (dysthymia and major depressive
disorder) and alcohol use (alcohol abuse and dependence)
disorders. Disorders were assessed using the definitions and
criteria of the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition [27]. Composite International
Diagnostic Interview organic exclusion rules were imposed
in making all diagnoses. WHO Composite International
Diagnostic Interview field trials and subsequent clinical
calibration studies had shown that the 12-month prevalence
rates of the disorders considered herein were assessed with
acceptable reliability [25].
2.4. Heart disease status
In a series of questions about chronic conditions adapted
from the U.S. Health Interview Survey [19], respondents
were asked about the presence of selected chronic condi-
tions. More specifically, respondents were asked if a medical
doctor or any other health professional had ever told them
that they had a heart disease. Self-reports of medically
diagnosed heart disease have been shown to have acceptable
validity, with some underreporting but little overreporting
[19–22]. Self-report measures of heart disease have been
used previously in research on heart disease and psycho-
pathology [28–31], but the limitations and potential biases ofWomen (%) Education
(%, secondary
or greater)
Heart disease prevalence rates b
Prevalence
(n)
Weighted
average (%)
54.5 46.4 108 3.0
52.3 31.4 78 2.3
53.0 83.2 399 7.0
53.7 70.0 70 6.1
47.5 61.4 129 10.1
48.1 46.8 100 12.4
52.2 60.4 504 6.7
51.7 69.7 105 8.9
52.2 NA 74 5.6
51.7 96.4 121 8.8
52.0 39.5 104 5.4
50.9 69.7 104 7.8
51.4 41.7 122 4.5
55.1 79.5 582 25.0
48.1 40.5 31 3.3
51.0 35.6 36 1.7
51.9 78.3 511 9.4
53.6 38.9 297 6.1
years), Japan (minimum age, 20 years) and Israel (minimum age, 21 years).
Table 2
Prevalence rates of mood disorders among persons with versus those without heart disease
Country Major depression Dysthymia
Without heart
disease (%)
With heart
disease (%)
OR (CI) Without heart
disease (%)
With heart
disease (%)
OR (CI)
Colombia 5.9 13.9 2.6 (1.5–4.8) * 0.9 5.0 5.6 (1.8–17.4) *
Mexico 4.0 8.7 2.1 (1.0–4.5) 0.9 0.9 0.8 (0.2–3.9)
United States 8.2 9.2 2.1 (1.4–3.2) * 2.2 3.7 2.6 (1.5–4.8) *
Japan 2.1 4.6 3.2 (1.1–8.9) * 0.6 2.7 4.6 (1.0–20.7) *
PRC Beijing 2.3 3.1 2.0 (1.0–4.0) 0.3 0.9 2.0 (0.4–9.4)
PRC Shanghai 0.9 6.9 7.4 (1.9–29.4) * 0.4 0.2 0.3 (0.0–4.8)
New Zealand 6.8 4.2 1.4 (0.9–2.3) 1.8 1.9 1.8 (1.0–3.3)
Belgium 5.6 5.6 1.9 (0.7–5.6) 1.1 3.0 2.3 (0.7–7.4)
France 6.1 6.4 2.1 (0.7–5.8) 1.6 1.4 0.9 (0.2–3.5)
Germany 3.0 3.3 2.0 (0.7–6.1) 0.7 3.1 4.2 (1.1–15.9) *
Italy 3.0 5.7 2.0 (1.0–4.3) 0.8 4.8 4.3 (2.2–8.3) *
The Netherlands 5.1 7.4 2.8 (1.0–7.8) * 1.7 2.9 3.8 (0.4–37.8)
Spain 3.9 7.4 2.3 (1.1–4.8) * 1.3 4.1 3.3 (1.3–8.5) *
Ukraine 6.4 18.6 2.5 (1.8–3.5) * 2.5 9.0 2.3 (1.6–3.3) *
Lebanon 1.8 1.3 1.2 (0.2–6.2) 0.7 0.0 NE
Nigeria 1.1 2.4 2.3 (0.8–6.5) 0.2 0.4 1.9 (0.2–21.6)
Israel 5.9 8.0 1.6 (1.0–2.4) * 1.1 2.1 1.7 (0.8–3.5)
South Africa 4.5 10.3 2.2 (1.4–3.6) * 0.1 0.0 NE
Pooled OR – – 2.1 (1.8–2.4) * – – 2.4 (2.0–3.0) *
NE, nonestimable.
*Pb.05.
Fig. 1. ORs (age and sex adjusted) for mood disorder among persons with
versus those without heart disease.
328 J. Ormel et al. / General Hospital Psychiatry 29 (2007) 325–334self-report of medically recognized heart disease need to be
considered in interpreting the results of the WMH surveys.
2.5. Data analysis
This article reports on prevalence rates for specific mental
disorders among persons with and those without heart
disease. For each survey, all odds ratios (ORs) quantifying
the association of each mental disorder with heart disease
were estimated while adjusting for age and sex. Ninety-five
percent confidence intervals (CIs) for the prevalence rates
and for the ORs were estimated using the Taylor series
method [32] with SUDAAN software [33] to adjust for
clustering and weighting. Pooled estimates of mental
disorder prevalence rates are not reported due to the large
variation in mental disorder prevalence rates across surveys.
Using meta-analytical methods, we calculated pooled
estimates of the ORs from the 18 surveys, describing the
overall association of each mental disorder with heart
disease. The pooled estimate of the OR was weighted by
the inverse of the variance of the estimate for each survey.
We report on the CIs of the pooled OR estimates [34]. For
each association of a specific mental disorder with heart
disease, we assessed whether the heterogeneity of the OR
estimates across surveys was greater than that expected by
chance [34]. Since these tests were nonsignificant except for
agoraphobia/panic disorder, we report on pooled estimates of
the ORs and CIs for those pooled estimates.
The adjusted ORs and the pooled estimates as well as
their CIs are displayed for each survey using a funnel graph
[35]. The funnel in these graphs shows the 95% CI band for a
survey estimate that would include the pooled estimate of theOR at varying levels of precision. Precision is defined as the
reciprocal of the standard error of the OR estimate. On these
graphs, the less precise estimates are on the left (where the
funnel is wider) and the more precise estimates are on the
right (where the funnel is narrower). These graphs provide a
visual summary of the association of any mood disorder and
that of any anxiety disorder with heart disease across the
participating surveys.
The prevalence of heart disease is so low among younger
people that the statistical adjustment for age may not be
entirely without risk as it might obscure differences in the
strength of the associations of interest between younger and
older respondents. Therefore, we reran the analyses
described above for respondents aged 50 years or older.
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3.1. Sample characteristics
Survey sample sizes ranged from 2372 (The Netherlands)
to 12,992 (New Zealand), with a total of 85,052 participating
adults in Part 1 and that of 43,249 in Part 2. Response rates
ranged from 45.9% (France) to 87.7% (Colombia), with a
sample size weighted average of 70.5% (Table 1).
Self-reported heart disease was common in all of the
participating countries. Excluding Ukraine, where the
prevalence of self-reported heart disease was exceptionallyTable 3
Prevalence rates of anxiety disorders among persons with versus those without he
Country Generalized anxiety
Without heart
disease (%)
With heart
disease (%)
OR (CI)
Colombia 1.0 1.5 1.6 (0.4–6.3
Mexico 0.5 1.0 1.7 (0.2–11
United States 4.0 4.9 1.9 (1.2–3.0
Japan 1.4 4.2 3.1 (0.9–10
PRC Beijing 1.0 2.4 2.0 (0.9–4.5
PRC Shanghai 0.2 4.6 12.3 (2.4–62
New Zealand 3.1 2.6 1.6 (0.9–2.6
Belgium 1.1 0.5 0.7 (0.2–2.7
France 1.9 5.3 5.7 (0.8–40
Germany 0.4 1.3 10.5 (1.5–74
Italy 0.5 0.8 2.0 (0.3–16
The Netherlands 1.1 0.5 0.5 (0.0–6.0
Spain 0.9 1.8 2.1 (0.6–7.5
Ukraine 1.3 5.4 3.3 (2.1–5.4
Lebanon 0.2 0.3 1.7 (0.2–15
Nigeria 0.0 0.0 NE
Israel 2.6 2.8 1.1 (0.6–2.1
South Africa 1.7 5.1 2.3 (1.1–4.9
Pooled OR – – 2.1 (1.7–2.5
Country Social phobia
Without heart
disease (%)
With heart
disease (%)
OR (CI)
Colombia 2.8 4.8 2.1 (0.8–5.1)
Mexico 1.9 5.0 2.9 (1.1–7.7)
United States 6.9 6.0 1.6 (1.0–2.6)
Japan 0.5 2.0 9.3 (1.7–51.2
PRC Beijing 0.3 0.7 5.3 (1.2–24.1
PRC Shanghai 0.0 0.0 NE
New Zealand 5.2 2.4 0.9 (0.5–1.6)
Belgium 1.2 0.4 1.6 (0.1–18.9
France 2.7 1.6 1.0 (0.1–7.7)
Germany 1.9 0.6 0.8 (0.2–3.6)
Italy 1.0 2.8 4.2 (0.9–19.1
The Netherlands 1.2 2.4 4.2 (1.2–14.7
Spain 0.7 0.9 4.0 (0.3–52.8
Ukraine 2.0 2.2 1.8 (0.9–4.0)
Lebanon 0.6 0.0 NE
Nigeria 0.3 0.0 NE
Israel – – NE
South Africa 1.7 5.0 3.4 (1.6–7.0)
Pooled OR – – 1.9 (1.5–2.5)
NE, nonestimable.
*Pb.05.high (25%), prevalence rates ranged from 1.7% in Nigeria to
12.4% in Shanghai, suggesting substantial across-country
variation (Table 1). European, Asian and North American
countries had a higher prevalence of heart disease as
compared with South American, Arabic Middle East and
African countries. Prevalence was higher among older
persons, among those with less than 12 years of education
and generally among men (data available upon request).
Exceptions to this pattern included Ukraine (31.0% pre-
valence for females vs. 17.5% for males) and Beijing (12.7%
prevalence for females vs. 7.7% for males).art disease
Agoraphobia or panic disorder
Without heart
disease (%)
With heart
disease (%)
OR (CI)
) 2.1 4.9 2.5 (1.0–6.3)
.6) 1.3 0.6 0.4 (0.1–1.9)
) * 3.6 4.0 2.0 (1.3–3.0) *
.9) 0.5 2.8 15.9 (4.4–58.0) *
) 0.4 0.3 0.7 (0.0–12.0)
.4) * 0.0 1.0 NE
) 2.2 2.2 2.4 (1.2–4.6) *
) 1.6 0.0 –
.7) 1.2 3.8 6.4 (1.7–24.7) *
.0) * 1.1 0.7 1.5 (0.3–7.5)
.5) 1.0 1.8 2.2 (0.4–11.0)
) 1.6 2.5 3.0 (0.9–10.0)
) 0.8 1.7 2.6 (0.7–8.9)
) * 0.9 4.7 4.9 (2.9–8.2) *
.3) 0.2 0.0 NE
0.2 6.0 32.6 (4.5–234.4) *
) 0.9 1.5 1.5 (0.7–3.4)
) * 5.1 13.0 2.7 (1.7–4.1) *
) * – – 2.7 (2.2–3.3) *
PTSD
Without heart
disease (%)
With heart
disease (%)
OR (CI)
0.6 0.5 0.9 (0.1–5.7)
* 0.6 1.1 2.5 (0.6–10.7)
3.5 4.8 2.7 (1.7–4.3) *
) * 0.4 0.0 NE
) * 0.2 0.8 3.3 (0.5–23.3)
0.1 0.4 6.8 (0.4–124.2)
3.0 3.0 1.5 (0.9–2.5)
) 0.7 0.8 2.7 (0.8–9.0)
2.3 2.4 2.2 (0.4–11.7)
0.7 0.7 3.2 (0.7–15.2)
) 0.7 1.6 1.9 (0.4–8.9)
) * 2.3 4.8 2.5 (0.4–14.1)
) 0.5 0.7 1.5 (0.3–6.3)
1.6 6.3 3.3 (1.9–5.6) *
1.7 0.9 1.1 (0.1–10.6)
0.0 0.0 NE
0.5 0.8 1.5 (0.3–7.0)
* 0.6 0.9 1.5 (0.3–7.4)
* – – 2.3 (1.8–2.9) *
Fig. 3. ORs (age and sex adjusted) for alcohol abuse/dependence among
persons with versus those without heart disease.
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Major depression was typically common among persons
with heart disease (Table 2) and generally fell in the range of
3–9%. The prevalence rates of dysthymia were typically
much lower, generally falling in the vicinity of 1–3%.
Comparisons of the prevalence rates of major depression and
dysthymia among persons with versus those without heart
disease showed small absolute differences in many countries,
with a few countries showing slightly lower prevalence rates
(b1%) among persons with heart disease (e.g., Lebanon), but
these unadjusted comparisons did not take age and sex
differences of persons with versus those without heart
disease into account.
As shown in Table 2, age- and sex-adjusted ORs
measuring the association of major depression with heart
disease were significantly greater than 1.0 (indicating a
positive association greater than that expected by chance) for
9 of the 18 surveys for which ORs were calculated. The
remaining ORs were all larger than 1.0. The ORs also
indicated a significant association between heart disease and
dysthymia for 7 of the 16 surveys for which ORs were
estimated. We assessed whether the variability in the OR
estimates across surveys was greater than that expected by
chance [34]. The resulting test of heterogeneity was
nonsignificant for major depression (P=.83) and dysthymia
(P=.38), thus making it appropriate to report on pooled
estimates. The pooled estimate of the OR for major
depression was 2.1, while the pooled estimate of the OR
for dysthymia was 2.4. In the subgroup of older respondents
(≥50 years), these ORs were 1.9 and 2.3, respectively.
Fig. 1 shows a funnel graph of the age- and sex-adjusted
ORs for mood disorders (major depression and/or dysthymia
present) for all 18 surveys. In this graph, the OR is plotted on
a log scale as a function of the precision of the estimate of the
OR. The funnel lines show whether the 95% CI of each
survey's estimate of the OR includes the pooled estimate,
given the precision of the survey's estimate. Most of the ORFig. 2. ORs (age and sex adjusted) for anxiety disorder among persons with
versus those without heart disease.estimates clustered in proximity to the pooled estimate of
2.1. The 95% CIs of all of the survey estimates included the
pooled estimate, with the more discrepant estimates tending
to be those with lower precision.
3.3. Anxiety disorders and heart disease
Across the surveys, the specific anxiety disorders (GAD,
panic disorder/agoraphobia, social phobia and PTSD) were
generally less prevalent as compared with major depression.
Among persons with heart disease, the prevalence rates of
GAD ranged from approximately 0.3% in Lebanon to
approximately 5% in Ukraine, the United States and France
(Table 3). The prevalence of agoraphobic/panic disorder
among persons with heart disease typically fell in the range
of 1–5% (Table 3). Social phobia was rarely found among
persons with heart disease in Beijing, Shanghai, Belgium,
Germany, Lebanon and Nigeria. The prevalence rates of
social phobia ranged from 1% (Spain) to 6% (United States)
among persons with heart disease in the remaining surveys
(Table 3). PTSD was relatively uncommon among persons
with heart disease in many of the participating surveys but
had a prevalence of 2% or higher in the United States,
France, Italy, The Netherlands and Ukraine (Table 3).
Because the specific anxiety disorders were less com-
mon, ORs were not estimated for all of the participating
surveys due to a null cell. Given the relatively small sample
sizes, it is not surprising that the OR estimates were often
not significantly different from 1.0, even when the OR
estimates were consistent with the pooled estimates. The
ORs for anxiety disorders tended to be greater than 1.0,
although the point estimates showed greater variability than
they did for mood disorders, possibly due to the lower
sample size of cases. The heterogeneity tests for the ORs
were nonsignificant for GAD (P=.12), social phobia (P=.08)
and PTSD (P=.90) but significant for agoraphobia/panic
disorder (P=.003), indicating that the pooled estimate for
this disorder masks significant heterogeneity across surveys.
Across the four anxiety disorders, the pooled OR estimates
331J. Ormel et al. / General Hospital Psychiatry 29 (2007) 325–334were all significantly greater than 1.0, falling in the range of
1.9–2.7. In the subgroup of older respondents (≥50 years
old), the ORs were also statistically significant and ranged
from 1.5 to 2.6.
The association of any anxiety disorder with heart disease
(Fig. 2) showed a pattern similar to that observed for any
mood disorder (Fig. 1). The pooled estimate of the OR was
2.2, with a 95% CI of 1.9 to 2.5. Of the 18 survey-specific
estimates, 14 had 95% CIs that included the pooled estimate.
Of the 4 estimates whose 95% CIs did not include the pooled
estimate, 2 had low precision (Nigeria and Shanghai) but 2
others had high precision (Israel and New Zealand). Overall,
these results indicate that the strength of the association of
anxiety disorders, as a class, with heart disease is comparable
with that observed for mood disorders — an odds of about
2:1 of anxiety disorder for persons with versus those without
heart disease.
3.4. Alcohol use disorders and heart disease
In 11 of the 18 surveys, as shown in Fig. 3 and Table 4,
1% or less of those with heart disease met the criteria for
alcohol abuse or dependence. In the remaining surveys, the
prevalence rates of alcohol abuse or dependence ranged from
1.4% (Japan) to about 4.5% (Mexico and Ukraine). ORs for
the association of alcohol abuse or dependence with heart
disease were estimated for 12 surveys. These ORs were
nearly all larger than 1.0 (except for New Zealand and
Israel), albeit not significantly. Since the prevalence of
alcohol use disorders decreases markedly with age but the
prevalence of heart disease increases with age, adjustment
for age and sex is important in assessing the associations.
The OR estimates were not found to be heterogeneous acrossTable 4
Prevalence rates of substance use disorders among persons with versus those
without heart disease
Country Alcohol abuse/dependence
Without heart
disease (%)
With heart
disease (%)
OR (CI)
Colombia 2.5 3.1 1.5 (0.3–7.3)
Mexico 2.2 4.2 3.2 (0.7–15.7)
United States 3.2 2.2 2.4 (1.0–5.8)
Japan 1.1 1.4 1.6 (0.2–16.4)
PRC Beijing 2.6 1.6 2.2 (0.4–12.5)
PRC Shanghai 0.4 0.6 2.2 (0.1–64.7)
New Zealand 3.0 0.4 0.7 (0.2–1.9)
Belgium 1.3 1.0 1.6 (0.2–15.4)
France 0.8 0.0 NE
Germany 1.3 0.0 NE
Italy 0.1 0.0 NE
The Netherlands 1.8 0.0 NE
Spain 0.3 0.0 NE
Ukraine 6.7 4.6 1.4 (0.7–2.9)
Lebanon 1.1 0.0 NE
Nigeria 0.7 0.9 2.2 (0.2–20.1)
Israel 1.2 0.4 0.8 (0.2–3.8)
South Africa 5.0 3.6 1.1 (0.5–2.1)
Pooled OR – – 1.4 (1.0–1.9)surveys (P=.86). The pooled estimate of the OR for the
association of alcohol abuse or dependence and heart disease
was 1.4, with a CI of 1.0 to 1.9. This marginally significant
association was not significant in the subgroup of older
respondents (OR=0.8). The 95% CIs of the survey-specific
estimates of the adjusted ORs for the association of heart
disease and alcohol abuse/dependence all included the
pooled estimates of the ORs. These results suggest that
alcohol abuse may occur with greater frequency among
persons with heart disease, although the results do not
indicate a strong association.4. Discussion
This report provides the first assessment of the frequency
and association of common mental disorders with self-
reported medically diagnosed heart disease in representative
population samples from diverse countries worldwide. Two
key findings emerged from this study: First, the well-known
association of depression with heart disease, which was
replicated here, was actually not stronger than the association
of anxiety disorders with heart disease. This held true for the
total population and for respondents aged 50 years or older.
The associations persist when adjusted for comorbidity of
depressive and anxiety disorders (data not presented but
available upon request). Second, since the participating
surveys included countries that differed markedly in culture,
language, level of socioeconomic development and pre-
valence of heart disease and mental disorders, the findings
hold true across diverse populations despite concerns about
differences in the validity of self-report of medically
recognized heart disease that may exist between developed
and developing countries.
Although the cross-sectional WMH surveys are cau-
sally noninformative, the key findings have implications
for current thinking about the depression–heart disease
association.
Various biobehavioral mechanisms have been proposed to
explain this association, including behavioral risk behaviors
(e.g., smoking, heavy alcohol use and physical inactivity),
poor treatment compliance, elevated levels of proinflamma-
tory cytokines, platelet activation, disturbances in the
autonomic nervous system (reduced heart rate variability),
hypothalamic–pituitary–adrenal axis dysfunction and the
stressfulness of heart disease-related events such as acute
myocardial infarction [4–6]. Our results suggest that the
implications of anxiety disorders for causal processes may
need to be given equal weight with those involving
depressive disorders. For instance, one proposed mechanism
is poor treatment compliance among depressed heart disease
patients, but it has been noted that anxiety disorders are
associated with good treatment compliance [36]. Other
mechanisms may need to be considered in light of the
comorbidity of heart disease with anxiety disorders as well as
mood disorders.
332 J. Ormel et al. / General Hospital Psychiatry 29 (2007) 325–334While self-reports of medically diagnosed heart disease
have generally good validity, with κ values exceeding 0.60,
considerable underreporting and some overreporting of
medically recorded heart disease have typically been found
[19–22]. Since the WMH surveys asked specifically for
medically diagnosed heart disease, it is less likely that
respondents reported atypical chest pain [37] and syndrome
X [38], although such an error cannot be excluded in a
questionnaire survey. Whether any misclassification is
nondifferential or produced significant bias is difficult to
determine as conclusive evidence either way is lacking. One
prior study found that negative affectivity (a trait associated
with psychological distress) is associated with self-report of
physical symptoms but not with self-report of medically
confirmed chronic disease [23]. The results for the depres-
sion–heart disease association reported here agree well with
those from prior studies in developed countries that used
objectively confirmed heart disease measures. This suggests
that it is reasonable to place some confidence in the validity
of the association of anxiety disorders with heart disease in
developed countries. This confidence may extend to less
developed countries since the patterns of association of
depression and anxiety disorders did not differ notably
between the two types of countries. All these do not negate
that the self-report of medically recognized heart disease
may differ in validity in developed versus less developed
countries. Neither can we rule out the possibility that those
with mental disorder were more likely to seek care for heart
disease symptoms and be labeled as having a heart disease.
This treatment seeking bias (Berkson's bias) may have
inflated associations. Given the overall pattern of results, we
think it is possible that misclassification is largely non-
differential and that underestimation of the association
between heart disease and mental disorder is slightly more
likely than serious bias. The limitations of these survey
results invite future research with more rigorous assessment
of heart disease status in developing countries than was
possible in this series of studies.
Another limitation of the WMH surveys is the lack of
more specific assessments of heart disease in terms of the
nature of the heart disease (e.g., rheumatic heart disease and
alcoholic cardiomyopathy) and the course of the disease
(e.g., post-myocardial infarction). More specific assessments
will also improve comparability with available studies that
focused on specific heart diseases and on specific phases in
their course.
The prevalence of heart disease in the WMH surveys
conformed to expected epidemiological patterns (i.e., increas-
ing prevalence with age, lower prevalence in relatively poor
countries and higher prevalence inmales in general). Also, the
exceedingly high prevalence of heart disease observed for
Ukraine is in line with findings of previous studies that many
Eastern European countries show cardiovascular disease rates
that are among the highest in the world [39]. However, we
have no ready explanation for the higher prevalence of heart
disease in females as compared with males in Ukraine, butcultural or linguistic factors might be involved [40]. The 12-
month prevalence estimates of major depression among
persons with heart disease in Western countries were
generally lower than had been reported in prior research [6].
This probably has two causes: First, the WMH study used
general population samples rather than persons identified in
health care settings, in which the prevalence of depression is
higher. Second, the WMH study assessed mental disorders
according to a standardized diagnostic instrument rather than
the percentage exceeding a predefined threshold on a self-
report depression symptom scale.5. Conclusions
The WMH surveys found that not only mood but also
anxiety disorders — as well as alcohol abuse disorders to a
lesser extent — occurred among persons with heart disease
at higher rates as compared with persons of comparable age
and sex without heart disease. This association was observed
across diverse countries differing in culture, language, level
of socioeconomic development and prevalence of mental
disorders. While this research does not shed light on whether
psychological disorders are causes or consequences of heart
disease, it does suggest that efforts to understand causal
relationships between heart disease and psychological illness
should consider culture-independent mechanisms that hold
true for mood and anxiety disorders. Since mood and anxiety
disorders are associated with many different chronic physical
conditions (e.g., [6]), the depression–heart disease link also
needs to be examined in the broader context of chronic
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